JPMorgan Starts Abbvie (ABBV) at Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500 and Nasdaq end higher on cool inflation data, solid bank earnings
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- Fed’s Warsh says central bank won’t tolerate high inflation
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- IBM misses Q2 targets as mainframe and software sales disappoint
- Verizon planning new round of layoffs this week - Barron’s
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
Barclays Starts Abbvie (ABBV) at Equalweight
January 4, 2013 8:05 AM ESTBarclays initiates coverage on Abbvie (NYSE: ABBV) with a Equalweight. PT $37.00.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $34.83 yesterday, with a 52 week range of $34.10-$35.40.... More
BMO Capital Starts Abbvie (ABBV) at Outperform
January 2, 2013 7:36 AM ESTBMO Capital initiates coverage on Abbvie (NYSE: ABBV) with a Outperform. PT $39.00.
For an analyst ratings summary and ratings history on Abbvie click here. For more ratings news on Abbvie click here.
Shares of Abbvie closed at $ yesterday, with a 52 week range of $-$.... More
